Elinzanetant (developmental code names BAY-3427080 GSK-1144814, NT-814) is an orally active small-molecule neurokinin/tachykinin NK 1 receptor and NK 3 receptor antagonist which is under development by Bayer, GlaxoSmithKline, and NeRRe Therapeutics for the treatment of hot flashes and "sex hormone disorders".

2024年5月16日 · Elinzanetant is a first dual neurokinin-1,3 (NK-1,3) receptor antagonist, in late-stage clinical development for the non-hormonal treatment of moderate to severe VMS associated with menopause, administered orally once daily.

2024年8月22日 · An experimental once-a-day pill that works without hormones significantly reduced the number of hot flashes experienced by women going through menopause and improved their sleep...

Meaning Elinzanetant is an efficacious and well-tolerated selective neurokinin-1,3 receptor antagonist for the treatment of moderate to severe VMS associated with menopause. Elinzanetant also improves sleep disturbances and menopause-related quality of life.

2024年10月9日 · Elinzanetant is the first dual neurokinin-1 and 3 (NK-1 and 3) receptor antagonist, in late-stage clinical development for the non-hormonal treatment of moderate to severe VMS associated with menopause, administered orally once daily.

2025年3月21日 · Bayer has filed for approval in the US for elinzanetant as a non-hormonal treatment for menopausal symptoms such as hot flushes, with a rival therapy from Astellas in its sights.

2025年1月15日 · According to the recently released results from OASIS 4, elinzanetant significantly reduced the frequency and severity of moderate to severe VMS in women receiving adjuvant endocrine therapy for hormone receptor–positive breast cancer or who are at high risk for the disease.

Elinzanetant is an orally bioavailable neurokinin/tachykinin 1 receptor (NK1-receptor; NK1R; NK-1R) and NK3 receptor (NK-3R; NK3R) antagonist, that may be used to treat vasomotor symptoms in menopausal woman.

2025年1月20日 · Elinzanetant achieved a statistically significant reduction in the frequency of moderate to severe VMS from baseline to weeks 4 and 12 compared to placebo. Notably, the treatment’s effects were observed as early as week 1 and …

2024年3月27日 · Elinzanetant is the first dual neurokinin (NK-1,3) receptor antagonist, in late-stage clinical development for the non-hormonal treatment of moderate to severe VMS associated with menopause, administered orally once daily.